World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward
- 1 January 2020
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 55 (1) , 105822
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- First Evaluation after Implementation of a Quality Control System for the Second Line Drug Susceptibility Testing of Mycobacterium tuberculosis Joint Efforts in Low and High Incidence CountriesPLOS ONE, 2013
- Linezolid for Treatment of Chronic Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2012
- Correction: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- Mitochondrial DNA Mutation Screening in an Ethnically Diverse Nonsyndromic Deafness CohortGenetic Testing and Molecular Biomarkers, 2012
- Hearing loss in patients on treatment for drug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Hearing in 44–45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort studyBMJ Open, 2012
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial DiseasesClinical Infectious Diseases, 2004
- Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosisAntimicrobial Agents and Chemotherapy, 1989
- A pilot study of two regiimens of thiacetazone plus isoniazid in the treatment of pulmonary tuberculosis in East AfricaTubercle, 1974